Psoriatic ArthritisRHUMPSONCT04800289
Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist/Dermatologist
An observational study of Psoriatic Arthritis, run by Centre Hospitalier le Mans at 1 site in France.
Trial summary
Current increase in the number of multidisciplinary consultations, but little documentation on their impact on patient management. More specifically, in the context of psoriatic arthritis, we are seeking to investigate the interest for the patient, through his or her satisfaction and the evolution of the activity of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Psoriatic Arthritis
- What is being tested?
- questionnaires
- How many people
- 600 participants
- Where
- 1 siteFrance
- Study dates
- 19 Jul 2020to 31 Jul 2030
- How long will I take part?
- 5 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients received in a joint rheumatologist/dermatologist consultation at the Le Mans Hospital
Who may be able to join
- All patients received in a joint rheumatologist/dermatologist consultation at the Le Mans Hospital
Who cannot join
- Diagnosis of psoriatic arthritis not retained
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre Hospitalier Du Mans
Le Mans, 72000
Christelle JADEAU, 02 44 71 07 81, cjadeau@ch-lemans.fr
About this study
Current increase in the number of multidisciplinary consultations, but little documentation on their impact on patient management. More specifically, in the context of psoriatic arthritis, we are seeking to investigate the interest for the patient, through his or her satisfaction and the evolution of the activity of his or her pathology, of a global, joint management in Rheumatology and Dermatology.
- Conditions
- Psoriatic Arthritis
- Being tested
- questionnaires
- Medical subject headings
- Arthritis, Psoriatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
questionnairesOther
questionnaires about disease and satisfaction of patient
What is being measured
The primary outcome is the main question the study is designed to answer.
impact on patient satisfaction and the evolution of their pathology of these mixed consultations, Dermatologist and Rheumatologist, in the context of psoriatic arthritis.
evaluate the impact on patient satisfaction and the evolution of their pathology of these mixed consultations, Dermatologist and Rheumatologist, in the context of psoriatic arthritis.
Measured: 5 years after inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2021
- Study start19 Jul 2020
- Primary completion31 Jul 2030 (estimated)
- Study completion31 Jul 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psoriatic ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier le Mans
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04800289
- Sponsor's protocol ID
- CHM-2019/S7/11
- Acronym
- RHUMPSO
- Status last verified
- Mar 2021
- First submitted
- 12 Mar 2021
- Last updated
- 16 Mar 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No